Turesson C, Jarenros A, Jacobsson L (2004) Increased incidence of cardiovascular disease in patients with rheumatoid arthritis: results from a community based study. Ann Rheum Dis 63:952–955. https://doi.org/10.1136/ard.2003.018101

Article  CAS  PubMed  PubMed Central  Google Scholar 

Van Doornum S, McColl G, Wicks IP (2002) Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum 46:862–873. https://doi.org/10.1002/art.10089

Article  PubMed  Google Scholar 

del Rincon ID, Williams K, Stern MP, Freeman GL, Escalante A (2001) High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 44:2737–2745. https://doi.org/10.1002/1529-0131(200112)44:12

Article  PubMed  Google Scholar 

Wallberg-Jonsson S, Ohman ML, Dahlqvist SR (1997) Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol 24:445–451

CAS  PubMed  Google Scholar 

Kerola AM, Kauppi MJ, Kerola T, Nieminen TV (2012) How early in the course of rheumatoid arthritis does the excess cardiovascular risk appear? Ann Rheum Dis 71:1606–1615. https://doi.org/10.1136/annrheumdis-2012-201334

Article  PubMed  Google Scholar 

Libby P, Ridker PM, Maseri A (2002) Inflammation and atherosclerosis. Circulation 105:1135–1143. https://doi.org/10.1161/hc0902.104353

Article  CAS  PubMed  Google Scholar 

Ross R (1999) Atherosclerosis–an inflammatory disease. N Engl J Med 340:115–126. https://doi.org/10.1056/NEJM199901143400207

Article  CAS  PubMed  Google Scholar 

Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL (2013) Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol 61:404–410. https://doi.org/10.1016/j.jacc.2012.10.027

Article  CAS  PubMed  Google Scholar 

Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ et al (2020) Colchicine in patients with chronic coronary disease. N Engl J Med 383:1838–1847. https://doi.org/10.1056/NEJMoa2021372

Article  CAS  PubMed  Google Scholar 

Bijl M (2003) Endothelial activation, endothelial dysfunction and premature atherosclerosis in systemic autoimmune diseases. Neth J Med 61:273–277

CAS  PubMed  Google Scholar 

Chen Q, Jin M, Yang F, Zhu J, Xiao Q, Zhang L (2013) Matrix metalloproteinases: inflammatory regulators of cell behaviors in vascular formation and remodeling. Mediators Inflamm 2013:928315. https://doi.org/10.1155/2013/928315

Article  CAS  PubMed  PubMed Central  Google Scholar 

Martinovic I, Abegunewardene N, Seul M, Vosseler M, Horstick G, Buerke M et al (2005) Elevated monocyte chemoattractant protein-1 serum levels in patients at risk for coronary artery disease. Circ J 69:1484–1489. https://doi.org/10.1253/circj.69.1484

Article  CAS  PubMed  Google Scholar 

Westra J, de Groot L, Plaxton SL, Brouwer E, Posthumus MD, Kallenberg CG, Bijl M (2011) Angiopoietin-2 is highly correlated with inflammation and disease activity in recent-onset rheumatoid arthritis and could be predictive for cardiovascular disease. Rheumatology (Oxford) 50:665–673. https://doi.org/10.1093/rheumatology/keq378

Article  CAS  PubMed  Google Scholar 

Holm PW, Slart RH, Zeebregts CJ, Hillebrands JL, Tio RA (2009) Atherosclerotic plaque development and instability: a dual role for VEGF. Ann Med 41:257–264. https://doi.org/10.1080/07853890802516507

Article  CAS  PubMed  Google Scholar 

Hu W, Wei R, Wang L, Lu J, Liu H, Zhang W (2018) Correlations of MMP-1, MMP-3, and MMP-12 with the degree of atherosclerosis, plaque stability and cardiovascular and cerebrovascular events. Exp Ther Med 15:1994–1998. https://doi.org/10.3892/etm.2017.5623

Article  CAS  PubMed  Google Scholar 

Herder C, Baumert J, Thorand B, Martin S, Lowel H, Kolb H, Koenig W (2006) Chemokines and incident coronary heart disease: results from the MONICA/KORA Augsburg case-cohort study, 1984–2002. Arterioscler Thromb Vasc Biol 26:2147–2152. https://doi.org/10.1161/01.ATV.0000235691.84430.86

Article  CAS  PubMed  Google Scholar 

Leavitt C, Zakai NA, Auer P, Cushman M, Lange EM, Levitan EB et al (2020) Interferon gamma-induced protein 10 (IP-10) and cardiovascular disease in African Americans. PLoS ONE 15:e0231013. https://doi.org/10.1371/journal.pone.0231013

Article  CAS  PubMed  PubMed Central  Google Scholar 

Martynowicz H, Janus A, Nowacki D, Mazur G (2014) The role of chemokines in hypertension. Adv Clin Exp Med. 23:319–325 https://doi.org/10.17219/acem/37123

Niki T, Soeki T, Yamaguchi K, Taketani Y, Yagi S, Iwase T et al (2015) Elevated Concentration of Interferon-Inducible Protein of 10 kD (IP-10) Is Associated With Coronary Atherosclerosis. Int Heart J 56:269–272. https://doi.org/10.1536/ihj.14-300

Article  CAS  PubMed  Google Scholar 

van Hooij A, Boeters DM, Tjon Kon Fat EM, van den Eeden SJF, Corstjens P, van der Helm-van Mil AHM, Geluk A (2017) Longitudinal IP-10 Serum Levels Are Associated with the Course of Disease Activity and Remission in Patients with Rheumatoid Arthritis. Clin Vaccine Immunol. 24 https://doi.org/10.1128/CVI.00060-17

Barath P, Fishbein MC, Cao J, Berenson J, Helfant RH, Forrester JS (1990) Detection and localization of tumor necrosis factor in human atheroma. Am J Cardiol 65:297–302. https://doi.org/10.1016/0002-9149(90)90291-8

Article  CAS  PubMed  Google Scholar 

Rathcke CN, Vestergaard H (2009) YKL-40–an emerging biomarker in cardiovascular disease and diabetes. Cardiovasc Diabetol 8:61. https://doi.org/10.1186/1475-2840-8-61

Article  CAS  PubMed  PubMed Central  Google Scholar 

Michelsen AE, Rathcke CN, Skjelland M, Holm S, Ranheim T, Krohg-Sorensen K et al (2010) Increased YKL-40 expression in patients with carotid atherosclerosis. Atherosclerosis 211:589–595. https://doi.org/10.1016/j.atherosclerosis.2010.02.035

Article  CAS  PubMed  Google Scholar 

Rattazzi M, Puato M, Faggin E, Bertipaglia B, Zambon A, Pauletto P (2003) C-reactive protein and interleukin-6 in vascular disease: culprits or passive bystanders? J Hypertens 21:1787–1803. https://doi.org/10.1097/00004872-200310000-00002

Article  CAS  PubMed  Google Scholar 

Wallace AM, McMahon AD, Packard CJ, Kelly A, Shepherd J, Gaw A, Sattar N (2001) Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation 104:3052–3056. https://doi.org/10.1161/hc5001.101061

Article  CAS  PubMed  Google Scholar 

Arnab B, Biswadip G, Arindam P, Shyamash M, Anirban G, Rajan P (2013) Anti-CCP antibody in patients with established rheumatoid arthritis: Does it predict adverse cardiovascular profile? J Cardiovasc Dis Res 4:102–106. https://doi.org/10.1016/j.jcdr.2012.09.003

Article  PubMed  PubMed Central  Google Scholar 

Gerli R, Sherer Y, Bocci EB, Vaudo G, Moscatelli S, Shoenfeld Y (2007) Precocious atherosclerosis in rheumatoid arthritis: role of traditional and disease-related cardiovascular risk factors. Ann N Y Acad Sci 1108:372–381. https://doi.org/10.1196/annals.1422.038

Article  CAS  PubMed  Google Scholar 

Lopez-Longo FJ, Oliver-Minarro D, de la Torre I, Gonzalez-Diaz de Rabago E, Sanchez-Ramon S, Rodriguez-Mahou M et al (2009) Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arthritis Rheum 61:419–424. https://doi.org/10.1002/art.24390

Article  CAS  PubMed  Google Scholar 

van Steenbergen HW, Aletaha D, Beaart-van de Voorde LJ, Brouwer E, Codreanu C, Combe B et al (2017) EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis. Ann Rheum Dis 76:491–496. https://doi.org/10.1136/annrheumdis-2016-209846

Article  PubMed